ZOLGENSMA
Dead / Abandoned — Abandoned — no statement of use filed (as of 12 Sept 2022)
What this means for you
This application is over — abandoned 12 Sept 2022. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 88566760
- Mark type
- Design + words
- Filed
- 05 Aug 2019
- Published for opposition
- 17 Dec 2019
- Abandoned
- 12 Sept 2022
- Attorney of record
- Maury M. Tepper, III
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations and gene therapy products in the nature of injectable biologic preparations for genetic, neurological, motor neuron, or neuromuscular diseases, disorders and conditions; pharmaceutical preparations and gene therapy products in the nature of biological preparations containing genetic materials for treating spinal muscular atrophy, loss of motor neurons, muscle degeneration, muscle weakness, and paralysis; gene therapy preparation in the nature of biological preparations containing genetic materials for sustained survival motor neuron protein expression
Owner
- NOVARTIS AG, BASEL, CH
- AveXis, Inc., Bannockburn, IL, US
- AveXis, Inc., Bannockburn, IL, US
Prosecution history
- 12 Sept 2022 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 12 Sept 2022 — ABANDONMENT - NO USE STATEMENT FILED
- 04 Feb 2022 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 02 Feb 2022 — SOU EXTENSION 4 GRANTED
- 02 Feb 2022 — SOU EXTENSION 4 FILED
- 02 Feb 2022 — SOU TEAS EXTENSION RECEIVED
- 05 Aug 2021 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 03 Aug 2021 — SOU EXTENSION 3 GRANTED
- 03 Aug 2021 — SOU EXTENSION 3 FILED
- 03 Aug 2021 — SOU TEAS EXTENSION RECEIVED
- 04 Feb 2021 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 02 Feb 2021 — SOU EXTENSION 2 GRANTED
- 02 Feb 2021 — SOU EXTENSION 2 FILED
- 02 Feb 2021 — SOU TEAS EXTENSION RECEIVED
- 08 Aug 2020 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED